RxDoctor Payments Data

Antonio Muina, MD

Hematology & Oncology · Miami, FLNPI 1386631562

Payments from drug & device makers

$348,784in general payments, 2019–2025

Across 104 payments — averaging $3353.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$174K
  • Exelixis Inc.$130K
  • E.r. Squibb & Sons, L.L.C.$34K
  • Eisai Inc.$11K
  • Seagen Inc.$125
  • Johnson & Johnson$85
  • plus $145 from 6 others

What the payments were for

  • Food & beverage$24474%
  • Education$8526%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.39$174,041
Exelixis Inc.30$129,638
E.r. Squibb & Sons, L.L.C.11$33,806
Eisai Inc.15$10,943
Seagen Inc.1$125
Johnson & Johnson1$85
Olympus America Inc.1$46
Merck2$43
Sumitomo Pharma America, Inc.1$17
Bayer1$15
180 Medical, Inc.1$13
Pfizer1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$348,784 in reported general payments places this provider in the 75th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$118,510
Medicare patients
381
Services billed
1,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide33$453,388
WeliregBelzutifan14$416,442
XtandiEnzalutamide30$415,760
CabometyxCabozantinib S-Malate13$329,898
LenvimaLenvatinib Mesylate12$292,524
OrgovyxRelugolix68$178,674
Abiraterone Acetate235$107,461
EliquisApixaban57$36,580
Everolimus17$11,235
Prednisone280$1,027
Bicalutamide42$854
Silodosin11$512
Tamsulosin Hcl26$337
Dexamethasone12$258
Gabapentin19$101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$15$453,38833 claims
MerckWelireg$43$416,44214 claims
Exelixis Inc.Cabometyx$129,638$329,89813 claims
Eisai Inc.Lenvima$10,943$292,52412 claims
Sumitomo Pharma America, Inc.Orgovyx$17$178,67468 claims
PfizerEliquis$11$36,58057 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →